Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.
Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback